Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| LGND | CLUSTER | neutral | 2/10 | Three directors sold a total of ~$1.95M in LGND shares over a 7-day window, representing only ~0.04% of the company's $5 | Jun 15, 2026 |
| CVKD | 144 | bearish | 5/10 | CEO Quang X. Pham filed a Form 144 on June 15, 2026, indicating intent to sell 40,000 shares of Cadrenal Therapeutics co | Jun 15, 2026 |
| PBYI | CLUSTER | neutral | 2/10 | Two directors at PUMA BIOTECHNOLOGY sold a combined $242K in open-market shares on June 12, 2026, representing just 0.06 | Jun 15, 2026 |
| ADTX | CLUSTER | bearish | 7/10 | Insider cluster at Aditxt shows 10% owners HRT Financial LP and Gong Sandie selling a combined 2.93M shares for ~$47K, w | Jun 15, 2026 |
| IPSC | CLUSTER | neutral | 2/10 | A cluster of insider transactions at Century Therapeutics shows a net selling direction, but the total value is only ~$5 | Jun 15, 2026 |
| IPSC | CLUSTER | neutral | 2/10 | Century Therapeutics insiders engaged in routine non-cash director grants (74,000 shares each to five directors) and min | Jun 15, 2026 |
| ABEO | CLUSTER | bearish | 5/10 | Five ABEO insiders, including the CEO and CFO, sold a total of $407K in open-market sales over a 7-day window. The clust | Jun 15, 2026 |
| ADPT | CLUSTER | neutral | 2/10 | Two C-suite insiders at Adaptive Biotechnologies sold a combined $790K in shares over a one-week window, representing ju | Jun 15, 2026 |
| ORKA | CLUSTER | neutral | 3/10 | Two ORKA insiders, a director and the SVP of Finance, sold $1.01M in open-market shares ($882K of that from director Car | Jun 15, 2026 |
| ORKA | CLUSTER | neutral | 2/10 | Four Oruka Therapeutics insiders (CEO, COO, General Counsel, and a Director) sold a total of ~$2.67M in open-market tran | Jun 15, 2026 |
| RARE | CLUSTER | neutral | 2/10 | Two insiders at Ultragenyx sold a combined $97K in open-market transactions on June 15, 2026. The EVP/Chief Legal Office | Jun 15, 2026 |
| ORKA | CLUSTER | neutral | 2/10 | Two insiders at Oruka Therapeutics, General Counsel Paul Quinlan and Director Carl Dambkowski, sold a combined $933K in | Jun 15, 2026 |
| ATRA | 3 | neutral | 2/10 | Brian N. Cherry filed a Form 3 initial statement of beneficial ownership, reporting 38,320 shares of Atara Biotherapeuti | Jun 15, 2026 |
| ANIP | CLUSTER | neutral | 2/10 | Three ANIP insiders (Director, CFO, and General Counsel) sold a total of $468K in open-market transactions over a 7-day | Jun 15, 2026 |
| LYEL | CLUSTER | neutral | 2/10 | Lyell Immunopharma insiders executed negligible open-market sales totaling $8K (0.003% of market cap) in early May 2026, | Jun 15, 2026 |
| RVMD | 144 | neutral | 2/10 | Director and Officer Mark A. Goldsmith filed a Form 144 indicating intent to sell 9,772 shares of Revolution Medicines c | Jun 15, 2026 |
| NATR | CLUSTER | neutral | 2/10 | Two EVP/Presidents at Nature's Sunshine Products sold a combined $262K in open-market transactions over a 7-day window. | Jun 15, 2026 |
| RVMD | 144 | neutral | 2/10 | Officer Stephen Michael Kelsey filed a Form 144 notice of intent to sell 4,071 shares of Revolution Medicines common sto | Jun 15, 2026 |
| ONC | CLUSTER | neutral | 2/10 | Five BeOne Medicines insiders, including the CEO, sold a total of $1.98M in open-market shares over a one-week window. T | Jun 15, 2026 |
| RVMD | 144 | neutral | 2/10 | Officer Margaret A. Horn filed a Form 144 notice of intent to sell 3,486 shares of Revolution Medicines common stock, va | Jun 15, 2026 |
| ONC | CLUSTER | neutral | 2/10 | Five insiders at BeOne Medicines (ONC) sold a total of $2.0M in shares on June 8, 2026, led by CEO John Oyler ($1.03M). | Jun 15, 2026 |
| ANAB | 144 | bearish | 6/10 | CEO Dennis Mulroy filed a Form 144 notice of intent to sell 20,000 shares of ANAB common stock, valued at approximately | Jun 15, 2026 |
| BFRG | 8-K | neutral | 2/10 | BullFrog AI Holdings filed an 8-K reporting a CEO salary increase from $400,000 to $600,000 and the results of its 2026 | Jun 15, 2026 |
| NNVC | S-3 | neutral | 3/10 | NanoViricides filed an S-3 registration statement to register 1,333,334 shares of common stock for resale by selling sto | Jun 15, 2026 |
| CVM | 424B5 | bearish | 6/10 | CEL-SCI is offering 2,500,000 shares at $1.00 per share in a best-efforts offering with no minimum, targeting $2.5M gros | Jun 15, 2026 |
| CRVO | 8-K | neutral | 2/10 | CervoMed Inc. filed an 8-K under Item 7.01 to disclose that an investor presentation has been made available on its webs | Jun 15, 2026 |
| RVMD | 144 | neutral | 2/10 | Margaret A. Horn, an officer at Revolution Medicines, filed a Form 144 to sell 90,000 common shares (~$13.85M at filing | Jun 15, 2026 |
| TARS | 144 | neutral | 2/10 | Director William J. Link filed a Form 144 notice of intent to sell 12,500 shares of Tarsus Pharmaceuticals common stock, | Jun 15, 2026 |
| PHVS | 144 | neutral | 2/10 | Director and Officer Berndt Modig filed a Form 144 to sell 2,291 shares of Pharvaris N.V. common stock, valued at approx | Jun 15, 2026 |
| ARDX | 144 | neutral | 3/10 | Director Michael Raab filed a Form 144 notice of intent to sell 125,000 shares of Ardelyx common stock, with an approxim | Jun 15, 2026 |